Report Thumbnail
Product Code QY0914914488HXV
Published Date 2024/6/24
QY Research
English105 PagesGlobal

Infectious Disease In-vitro Diagnostic - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030 ‐ Pharmaceutical_LifeSciense Market


Report Thumbnail
Product Code QY0914914488HXV◆The Jun 2025 edition is also likely available. We will check with the publisher immediately.
Published Date 2024/6/24
QY Research
English 105 PagesGlobal

Infectious Disease In-vitro Diagnostic - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030 ‐ Pharmaceutical_LifeSciense Market


Abstract

Summary

The global market for Infectious Disease In-vitro Diagnostic was estimated to be worth US$ 56 million in 2023 and is forecast to a readjusted size of US$ 85 million by 2030 with a CAGR of 3.9% during the forecast period 2024-2030
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Infectious Disease In-vitro Diagnostic, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Infectious Disease In-vitro Diagnostic by region & country, by Type, and by Application.
The Infectious Disease In-vitro Diagnostic market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Infectious Disease In-vitro Diagnostic.
Market Segmentation
By Company
BD
BioMérieux SA
Abbott
Quidel Corporation
OraSure Technologies, Inc.
Hologic, Inc. (Gen Probe)
Danaher
QIAGEN
Roche
Siemens Healthineers AG
Bio-Rad Laboratories, Inc.
Segment by Type:
Immunoassay
Molecular Diagnostics
Microbiology
Others
Segment by Application
COVID-19
MRSA
Clostridium Difficile
Respiratory Virus
TB and Drug-resistant TB
Chlamydia
Gonorrhea
HPV
HIV
Others(Gastro-intestinal Panel Testing, Hepatitis C, Hepatitis B, etc)
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Infectious Disease In-vitro Diagnostic manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Infectious Disease In-vitro Diagnostic in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Infectious Disease In-vitro Diagnostic in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Table of Contents

  • 1 Market Overview

    • 1.1 Infectious Disease In-vitro Diagnostic Product Introduction
    • 1.2 Global Infectious Disease In-vitro Diagnostic Market Size Forecast
    • 1.3 Infectious Disease In-vitro Diagnostic Market Trends & Drivers
      • 1.3.1 Infectious Disease In-vitro Diagnostic Industry Trends
      • 1.3.2 Infectious Disease In-vitro Diagnostic Market Drivers & Opportunity
      • 1.3.3 Infectious Disease In-vitro Diagnostic Market Challenges
      • 1.3.4 Infectious Disease In-vitro Diagnostic Market Restraints
    • 1.4 Assumptions and Limitations
    • 1.5 Study Objectives
    • 1.6 Years Considered

  • 2 Competitive Analysis by Company

    • 2.1 Global Infectious Disease In-vitro Diagnostic Players Revenue Ranking (2023)
    • 2.2 Global Infectious Disease In-vitro Diagnostic Revenue by Company (2019-2024)
    • 2.3 Key Companies Infectious Disease In-vitro Diagnostic Manufacturing Base Distribution and Headquarters
    • 2.4 Key Companies Infectious Disease In-vitro Diagnostic Product Offered
    • 2.5 Key Companies Time to Begin Mass Production of Infectious Disease In-vitro Diagnostic
    • 2.6 Infectious Disease In-vitro Diagnostic Market Competitive Analysis
      • 2.6.1 Infectious Disease In-vitro Diagnostic Market Concentration Rate (2019-2024)
      • 2.6.2 Global 5 and 10 Largest Companies by Infectious Disease In-vitro Diagnostic Revenue in 2023
      • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Infectious Disease In-vitro Diagnostic as of 2023)
    • 2.7 Mergers & Acquisitions, Expansion

  • 3 Segmentation by Type

    • 3.1 Introduction by Type
      • 3.1.1 Immunoassay
      • 3.1.2 Molecular Diagnostics
      • 3.1.3 Microbiology
      • 3.1.4 Others
    • 3.2 Global Infectious Disease In-vitro Diagnostic Sales Value by Type
      • 3.2.1 Global Infectious Disease In-vitro Diagnostic Sales Value by Type (2019 VS 2023 VS 2030)
      • 3.2.2 Global Infectious Disease In-vitro Diagnostic Sales Value, by Type (2019-2030)
      • 3.2.3 Global Infectious Disease In-vitro Diagnostic Sales Value, by Type (%) (2019-2030)

  • 4 Segmentation by Application

    • 4.1 Introduction by Application
      • 4.1.1 COVID-19
      • 4.1.2 MRSA
      • 4.1.3 Clostridium Difficile
      • 4.1.4 Respiratory Virus
      • 4.1.5 TB and Drug-resistant TB
      • 4.1.6 Chlamydia
      • 4.1.7 Gonorrhea
      • 4.1.8 HPV
      • 4.1.9 HIV
      • 4.1.10 Others(Gastro-intestinal Panel Testing, Hepatitis C, Hepatitis B, etc)
    • 4.2 Global Infectious Disease In-vitro Diagnostic Sales Value by Application
      • 4.2.1 Global Infectious Disease In-vitro Diagnostic Sales Value by Application (2019 VS 2023 VS 2030)
      • 4.2.2 Global Infectious Disease In-vitro Diagnostic Sales Value, by Application (2019-2030)
      • 4.2.3 Global Infectious Disease In-vitro Diagnostic Sales Value, by Application (%) (2019-2030)

  • 5 Segmentation by Region

    • 5.1 Global Infectious Disease In-vitro Diagnostic Sales Value by Region
      • 5.1.1 Global Infectious Disease In-vitro Diagnostic Sales Value by Region: 2019 VS 2023 VS 2030
      • 5.1.2 Global Infectious Disease In-vitro Diagnostic Sales Value by Region (2019-2024)
      • 5.1.3 Global Infectious Disease In-vitro Diagnostic Sales Value by Region (2025-2030)
      • 5.1.4 Global Infectious Disease In-vitro Diagnostic Sales Value by Region (%), (2019-2030)
    • 5.2 North America
      • 5.2.1 North America Infectious Disease In-vitro Diagnostic Sales Value, 2019-2030
      • 5.2.2 North America Infectious Disease In-vitro Diagnostic Sales Value by Country (%), 2023 VS 2030
    • 5.3 Europe
      • 5.3.1 Europe Infectious Disease In-vitro Diagnostic Sales Value, 2019-2030
      • 5.3.2 Europe Infectious Disease In-vitro Diagnostic Sales Value by Country (%), 2023 VS 2030
    • 5.4 Asia Pacific
      • 5.4.1 Asia Pacific Infectious Disease In-vitro Diagnostic Sales Value, 2019-2030
      • 5.4.2 Asia Pacific Infectious Disease In-vitro Diagnostic Sales Value by Country (%), 2023 VS 2030
    • 5.5 South America
      • 5.5.1 South America Infectious Disease In-vitro Diagnostic Sales Value, 2019-2030
      • 5.5.2 South America Infectious Disease In-vitro Diagnostic Sales Value by Country (%), 2023 VS 2030
    • 5.6 Middle East & Africa
      • 5.6.1 Middle East & Africa Infectious Disease In-vitro Diagnostic Sales Value, 2019-2030
      • 5.6.2 Middle East & Africa Infectious Disease In-vitro Diagnostic Sales Value by Country (%), 2023 VS 2030

  • 6 Segmentation by Key Countries/Regions

    • 6.1 Key Countries/Regions Infectious Disease In-vitro Diagnostic Sales Value Growth Trends, 2019 VS 2023 VS 2030
    • 6.2 Key Countries/Regions Infectious Disease In-vitro Diagnostic Sales Value
    • 6.3 United States
      • 6.3.1 United States Infectious Disease In-vitro Diagnostic Sales Value, 2019-2030
      • 6.3.2 United States Infectious Disease In-vitro Diagnostic Sales Value by Type (%), 2023 VS 2030
      • 6.3.3 United States Infectious Disease In-vitro Diagnostic Sales Value by Application, 2023 VS 2030
    • 6.4 Europe
      • 6.4.1 Europe Infectious Disease In-vitro Diagnostic Sales Value, 2019-2030
      • 6.4.2 Europe Infectious Disease In-vitro Diagnostic Sales Value by Type (%), 2023 VS 2030
      • 6.4.3 Europe Infectious Disease In-vitro Diagnostic Sales Value by Application, 2023 VS 2030
    • 6.5 China
      • 6.5.1 China Infectious Disease In-vitro Diagnostic Sales Value, 2019-2030
      • 6.5.2 China Infectious Disease In-vitro Diagnostic Sales Value by Type (%), 2023 VS 2030
      • 6.5.3 China Infectious Disease In-vitro Diagnostic Sales Value by Application, 2023 VS 2030
    • 6.6 Japan
      • 6.6.1 Japan Infectious Disease In-vitro Diagnostic Sales Value, 2019-2030
      • 6.6.2 Japan Infectious Disease In-vitro Diagnostic Sales Value by Type (%), 2023 VS 2030
      • 6.6.3 Japan Infectious Disease In-vitro Diagnostic Sales Value by Application, 2023 VS 2030
    • 6.7 South Korea
      • 6.7.1 South Korea Infectious Disease In-vitro Diagnostic Sales Value, 2019-2030
      • 6.7.2 South Korea Infectious Disease In-vitro Diagnostic Sales Value by Type (%), 2023 VS 2030
      • 6.7.3 South Korea Infectious Disease In-vitro Diagnostic Sales Value by Application, 2023 VS 2030
    • 6.8 Southeast Asia
      • 6.8.1 Southeast Asia Infectious Disease In-vitro Diagnostic Sales Value, 2019-2030
      • 6.8.2 Southeast Asia Infectious Disease In-vitro Diagnostic Sales Value by Type (%), 2023 VS 2030
      • 6.8.3 Southeast Asia Infectious Disease In-vitro Diagnostic Sales Value by Application, 2023 VS 2030
    • 6.9 India
      • 6.9.1 India Infectious Disease In-vitro Diagnostic Sales Value, 2019-2030
      • 6.9.2 India Infectious Disease In-vitro Diagnostic Sales Value by Type (%), 2023 VS 2030
      • 6.9.3 India Infectious Disease In-vitro Diagnostic Sales Value by Application, 2023 VS 2030

  • 7 Company Profiles

    • 7.1 BD
      • 7.1.1 BD Profile
      • 7.1.2 BD Main Business
      • 7.1.3 BD Infectious Disease In-vitro Diagnostic Products, Services and Solutions
      • 7.1.4 BD Infectious Disease In-vitro Diagnostic Revenue (US$ Million) & (2019-2024)
      • 7.1.5 BD Recent Developments
    • 7.2 BioMérieux SA
      • 7.2.1 BioMérieux SA Profile
      • 7.2.2 BioMérieux SA Main Business
      • 7.2.3 BioMérieux SA Infectious Disease In-vitro Diagnostic Products, Services and Solutions
      • 7.2.4 BioMérieux SA Infectious Disease In-vitro Diagnostic Revenue (US$ Million) & (2019-2024)
      • 7.2.5 BioMérieux SA Recent Developments
    • 7.3 Abbott
      • 7.3.1 Abbott Profile
      • 7.3.2 Abbott Main Business
      • 7.3.3 Abbott Infectious Disease In-vitro Diagnostic Products, Services and Solutions
      • 7.3.4 Abbott Infectious Disease In-vitro Diagnostic Revenue (US$ Million) & (2019-2024)
      • 7.3.5 Quidel Corporation Recent Developments
    • 7.4 Quidel Corporation
      • 7.4.1 Quidel Corporation Profile
      • 7.4.2 Quidel Corporation Main Business
      • 7.4.3 Quidel Corporation Infectious Disease In-vitro Diagnostic Products, Services and Solutions
      • 7.4.4 Quidel Corporation Infectious Disease In-vitro Diagnostic Revenue (US$ Million) & (2019-2024)
      • 7.4.5 Quidel Corporation Recent Developments
    • 7.5 OraSure Technologies, Inc.
      • 7.5.1 OraSure Technologies, Inc. Profile
      • 7.5.2 OraSure Technologies, Inc. Main Business
      • 7.5.3 OraSure Technologies, Inc. Infectious Disease In-vitro Diagnostic Products, Services and Solutions
      • 7.5.4 OraSure Technologies, Inc. Infectious Disease In-vitro Diagnostic Revenue (US$ Million) & (2019-2024)
      • 7.5.5 OraSure Technologies, Inc. Recent Developments
    • 7.6 Hologic, Inc. (Gen Probe)
      • 7.6.1 Hologic, Inc. (Gen Probe) Profile
      • 7.6.2 Hologic, Inc. (Gen Probe) Main Business
      • 7.6.3 Hologic, Inc. (Gen Probe) Infectious Disease In-vitro Diagnostic Products, Services and Solutions
      • 7.6.4 Hologic, Inc. (Gen Probe) Infectious Disease In-vitro Diagnostic Revenue (US$ Million) & (2019-2024)
      • 7.6.5 Hologic, Inc. (Gen Probe) Recent Developments
    • 7.7 Danaher
      • 7.7.1 Danaher Profile
      • 7.7.2 Danaher Main Business
      • 7.7.3 Danaher Infectious Disease In-vitro Diagnostic Products, Services and Solutions
      • 7.7.4 Danaher Infectious Disease In-vitro Diagnostic Revenue (US$ Million) & (2019-2024)
      • 7.7.5 Danaher Recent Developments
    • 7.8 QIAGEN
      • 7.8.1 QIAGEN Profile
      • 7.8.2 QIAGEN Main Business
      • 7.8.3 QIAGEN Infectious Disease In-vitro Diagnostic Products, Services and Solutions
      • 7.8.4 QIAGEN Infectious Disease In-vitro Diagnostic Revenue (US$ Million) & (2019-2024)
      • 7.8.5 QIAGEN Recent Developments
    • 7.9 Roche
      • 7.9.1 Roche Profile
      • 7.9.2 Roche Main Business
      • 7.9.3 Roche Infectious Disease In-vitro Diagnostic Products, Services and Solutions
      • 7.9.4 Roche Infectious Disease In-vitro Diagnostic Revenue (US$ Million) & (2019-2024)
      • 7.9.5 Roche Recent Developments
    • 7.10 Siemens Healthineers AG
      • 7.10.1 Siemens Healthineers AG Profile
      • 7.10.2 Siemens Healthineers AG Main Business
      • 7.10.3 Siemens Healthineers AG Infectious Disease In-vitro Diagnostic Products, Services and Solutions
      • 7.10.4 Siemens Healthineers AG Infectious Disease In-vitro Diagnostic Revenue (US$ Million) & (2019-2024)
      • 7.10.5 Siemens Healthineers AG Recent Developments
    • 7.11 Bio-Rad Laboratories, Inc.
      • 7.11.1 Bio-Rad Laboratories, Inc. Profile
      • 7.11.2 Bio-Rad Laboratories, Inc. Main Business
      • 7.11.3 Bio-Rad Laboratories, Inc. Infectious Disease In-vitro Diagnostic Products, Services and Solutions
      • 7.11.4 Bio-Rad Laboratories, Inc. Infectious Disease In-vitro Diagnostic Revenue (US$ Million) & (2019-2024)
      • 7.11.5 Bio-Rad Laboratories, Inc. Recent Developments

  • 8 Industry Chain Analysis

    • 8.1 Infectious Disease In-vitro Diagnostic Industrial Chain
    • 8.2 Infectious Disease In-vitro Diagnostic Upstream Analysis
      • 8.2.1 Key Raw Materials
      • 8.2.2 Raw Materials Key Suppliers
      • 8.2.3 Manufacturing Cost Structure
    • 8.3 Midstream Analysis
    • 8.4 Downstream Analysis (Customers Analysis)
    • 8.5 Sales Model and Sales Channels
      • 8.5.1 Infectious Disease In-vitro Diagnostic Sales Model
      • 8.5.2 Sales Channel
      • 8.5.3 Infectious Disease In-vitro Diagnostic Distributors

  • 9 Research Findings and Conclusion

  • 10 Appendix

    • 10.1 Research Methodology
      • 10.1.1 Methodology/Research Approach
      • 10.1.2 Data Source
    • 10.2 Author Details
    • 10.3 Disclaimer
USD 3,950 or Partial Purchase
*Prices are subject to change by the publisher.
© 2026 ShareFair Inc.